ID   TAW-925
AC   CVCL_Z044
DR   Wikidata; Q54971738
RX   Patent=EP0305960A2;
RX   Patent=EP0336405B1;
RX   PubMed=3030301;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50095.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:472805; Ouabain.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6544 ! WIL2
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 12
//
RX   Patent=EP0305960A2;
RA   Iwasa S., Ichimori Y., Kuriyama M.;
RT   "A transformant cell line capable of producing a human monoclonal
RT   antibody, hybridoma, their production and use.";
RL   Patent number EP0305960A2, 08-Mar-1989.
//
RX   Patent=EP0336405B1;
RA   Iwasa S., Kuriyama M., Okazaki K., Toyoda Y.;
RT   "Anti-human cancer protein complexes, their production and use.";
RL   Patent number EP0336405B1, 13-Jan-1993.
//
RX   PubMed=3030301; DOI=10.1016/0006-291X(87)91485-9;
RA   Ichimori Y., Harada K., Hitotsumachi S., Tsukamoto K.;
RT   "Establishment of hybridoma secreting human monoclonal antibody
RT   against hepatitis B virus surface antigen.";
RL   Biochem. Biophys. Res. Commun. 142:805-812(1987).
//